数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert J. Greenberg Director 48 2.50万美元 未持股 2017-04-18
Darrin R. Uecker President and Chief Executive Officer and Director 51 39.36万美元 未持股 2017-04-18
Robert M. Levande Chairman of the Board 67 2.50万美元 未持股 2017-04-18
Mitchell E. Levinson Director 57 2.50万美元 未持股 2017-04-18
Thierry B. Thaure Director 54 2.50万美元 未持股 2017-04-18
Maky Zanganeh -- Director 46 未披露 未持股 2017-04-18

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Darrin R. Uecker President and Chief Executive Officer and Director 51 39.36万美元 未持股 2017-04-18
Brian B. Dow Chief Financial Officer, Senior Vice President, Treasurer and Secretary 55 28.58万美元 未持股 2017-04-18

董事简历

中英对照 |  中文 |  英文
Robert J. Greenberg

Robert J. Greenberg,自2015年5月起担任董事;1998年12月至2015年8月间担任Second Sight Medical Products, Inc.的总裁、首席执行官兼董事;自2015年8月起担任Second Sight的董事长。在Second Sight成立前,1998年4月至12月,他联席管理the Alfred E. Mann Foundation,自2007年2月起担任其董事长;1997年至1998年间担任the United States Food and Drug Administration神经病学设备部门的设备评估办公室的IDEs and 510ks首席评估员。1998年,他获得了The Johns Hopkins School of Medicine的医学学位。他于1991年至1997年间领导针对色素性视网膜炎患者进行视网膜电刺激可行性研究的临床前试验,这一试验在巴尔的摩the Wilmer Eye Institute at Johns Hopkins完成,并使他获得了the Johns Hopkins Department of Biomedical Engineering的博士学位。他获得了Duke University的电气工程和生物医学工程学士学位。他独特而丰富的科学、技术和商业经验使他胜任董事一职。


Robert J. Greenberg has been a member of our Board of Directors since May 2015. He served as President, Chief Executive Officer and Director of Second Sight Medical Products, Inc. from December 1998 through August 2015. Since August 2015 he became chairman of the board at Second Sight. Prior to the formation of Second Sight, Dr. Greenberg worked co-managing the Alfred E. Mann Foundation from April 1998 to December 1998 and since February 2007 he has been chairman of that foundation. From 1997 to 1998 he served as lead reviewer for IDEs and 510ks at the Office of Device Evaluation at the United States Food and Drug Administration in the Neurological Devices Division. In 1998 he received his medical degree from The Johns Hopkins School of Medicine. From 1991 to 1997 Dr. Greenberg conducted pre-clinical trials demonstrating the feasibility of retinal electrical stimulation in patients with retinitis pigmentosa. This work was done at the Wilmer Eye Institute at Johns Hopkins in Baltimore and led to the granting of his Ph.D. from the Johns Hopkins Department of Biomedical Engineering. His undergraduate degree was in Electrical Engineering and Biomedical Engineering from Duke University.
Robert J. Greenberg,自2015年5月起担任董事;1998年12月至2015年8月间担任Second Sight Medical Products, Inc.的总裁、首席执行官兼董事;自2015年8月起担任Second Sight的董事长。在Second Sight成立前,1998年4月至12月,他联席管理the Alfred E. Mann Foundation,自2007年2月起担任其董事长;1997年至1998年间担任the United States Food and Drug Administration神经病学设备部门的设备评估办公室的IDEs and 510ks首席评估员。1998年,他获得了The Johns Hopkins School of Medicine的医学学位。他于1991年至1997年间领导针对色素性视网膜炎患者进行视网膜电刺激可行性研究的临床前试验,这一试验在巴尔的摩the Wilmer Eye Institute at Johns Hopkins完成,并使他获得了the Johns Hopkins Department of Biomedical Engineering的博士学位。他获得了Duke University的电气工程和生物医学工程学士学位。他独特而丰富的科学、技术和商业经验使他胜任董事一职。
Robert J. Greenberg has been a member of our Board of Directors since May 2015. He served as President, Chief Executive Officer and Director of Second Sight Medical Products, Inc. from December 1998 through August 2015. Since August 2015 he became chairman of the board at Second Sight. Prior to the formation of Second Sight, Dr. Greenberg worked co-managing the Alfred E. Mann Foundation from April 1998 to December 1998 and since February 2007 he has been chairman of that foundation. From 1997 to 1998 he served as lead reviewer for IDEs and 510ks at the Office of Device Evaluation at the United States Food and Drug Administration in the Neurological Devices Division. In 1998 he received his medical degree from The Johns Hopkins School of Medicine. From 1991 to 1997 Dr. Greenberg conducted pre-clinical trials demonstrating the feasibility of retinal electrical stimulation in patients with retinitis pigmentosa. This work was done at the Wilmer Eye Institute at Johns Hopkins in Baltimore and led to the granting of his Ph.D. from the Johns Hopkins Department of Biomedical Engineering. His undergraduate degree was in Electrical Engineering and Biomedical Engineering from Duke University.
Darrin R. Uecker

Darrin R. Uecker,自2015年9月起担任首席执行官、总裁兼董事。他有着超过20年的医疗器械领域经验。他于2014年1月至2015年9月间担任加州门罗帕克市Progyny, Inc.(开发EevaTM,这是世界上第一个在体外受精时进行受精卵筛选的自动延时系统)的总裁兼首席运营官;2009年6月至2014年1月间担任加州雷德伍德城Gynesonics, Inc.(利用超声引导射频消融技术开发针对症状性子宫肌瘤疗法的新型医疗器械)的首席执行官、总裁兼董事;2008年6月至2009年6月间担任CyperHeart, Inc.(开发外辐射平台,用于治疗心律失常)的高级副总裁等多个职位;2007年5月至2008年6月间担任Conceptus, Inc.的高级副总裁,2004年1月至2007年1月间担任RITA Medical Systems, Inc.(医疗器械公司,关注肿瘤治疗的烧灼疗法)的首席技术官。他被任命为董事是由于他在圣塔芭芭拉the University of California电子和计算机工程的教育背景。


Darrin R. Uecker has been our Chief Executive Officer and President and a director since September 2015. Mr. Uecker has over 20 years of experience in the medical device field. From January 2014 to September 2015 Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. From June 2009 to January 2014 Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Prior to that, Mr. Uecker served in a variety of executive level roles, including as a Senior Vice President at CyperHeart, Inc. June 2008 to June 2009 a company that developed an external beam radiation platform for the treatment of heart arrhythmias, a Senior Vice President at Conceptus, Inc. (May 2007 to June 2008), and as Chief Technology Officer at RITA Medical Systems, Inc. (January 2004 to January 2007), a medical device oncology company focused on ablative therapies. Mr. Uecker holds a M.S. degree in Electrical and Computer Engineering from the University of California at Santa Barbara.
Darrin R. Uecker,自2015年9月起担任首席执行官、总裁兼董事。他有着超过20年的医疗器械领域经验。他于2014年1月至2015年9月间担任加州门罗帕克市Progyny, Inc.(开发EevaTM,这是世界上第一个在体外受精时进行受精卵筛选的自动延时系统)的总裁兼首席运营官;2009年6月至2014年1月间担任加州雷德伍德城Gynesonics, Inc.(利用超声引导射频消融技术开发针对症状性子宫肌瘤疗法的新型医疗器械)的首席执行官、总裁兼董事;2008年6月至2009年6月间担任CyperHeart, Inc.(开发外辐射平台,用于治疗心律失常)的高级副总裁等多个职位;2007年5月至2008年6月间担任Conceptus, Inc.的高级副总裁,2004年1月至2007年1月间担任RITA Medical Systems, Inc.(医疗器械公司,关注肿瘤治疗的烧灼疗法)的首席技术官。他被任命为董事是由于他在圣塔芭芭拉the University of California电子和计算机工程的教育背景。
Darrin R. Uecker has been our Chief Executive Officer and President and a director since September 2015. Mr. Uecker has over 20 years of experience in the medical device field. From January 2014 to September 2015 Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. From June 2009 to January 2014 Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Prior to that, Mr. Uecker served in a variety of executive level roles, including as a Senior Vice President at CyperHeart, Inc. June 2008 to June 2009 a company that developed an external beam radiation platform for the treatment of heart arrhythmias, a Senior Vice President at Conceptus, Inc. (May 2007 to June 2008), and as Chief Technology Officer at RITA Medical Systems, Inc. (January 2004 to January 2007), a medical device oncology company focused on ablative therapies. Mr. Uecker holds a M.S. degree in Electrical and Computer Engineering from the University of California at Santa Barbara.
Robert M. Levande

Robert M. Levande,自2014年5月起担任董事,自2014年7月起担任董事长;2014年5月至2015年9月间担任副总裁。此外,他曾自我公司子公司NanoBlate Inc.和BioElectroMed Corp.于2014年11月成立起担任其唯一董事兼总裁,至2015年9月止。 他也是MDB Capital Group, LLC的高级常务董事,于2003年加入该公司。在加入MDB Capital Group, LLC之前,他于2001年12月至2003年5月间担任Gilford Securities的生命科学企业财务联席主管。此前,他成立了the Palantir Group, Inc., 1998年1月至2001年12月间,致力于为医疗技术行业提供业务开发、并购、筹资战略建议。1972年至1999年,他在Pfizer Inc.担任多个执行职位,级别渐升,主要在其医疗技术组(MTG),围绕一般管理、运营、财务、营销和业务开发。他的其他经验包括:Orthovita, Inc. (纳斯达克: VITA)的董事(2000.5-2007.7),VirnetX Inc.(现为VirnetX Holding Corp. (纽交所: MKT: VHC)的创始人/董事(2005-2007)。他自2008年起担任Integrated Surgical Systems (OTC: ISSM.PK)的董事。他获得了Columbia University的工商管理硕士学位,以及the University of Pennsylvania Wharton School of Finance & Commerce的经济学学士学位。


Robert M. Levande has been a member of our Board of Directors since May 2014 and Chairman of our Board of Directors since July 2015. Mr. Levande is one of our co-founders and a former officer of the Company. Mr. Levande is a senior managing director at MDB Capital Group, LLC, which he joined in 2003. Prior to joining MDB Capital Group, LLC, Mr. Levande was co-head of Life Sciences Corporate Finance at Gilford Securities Incorporated from December 2001 to May 2003. Previously, he founded the Palantir Group, Inc., which specializes in providing strategic advice in business development, mergers, acquisitions, and capital raising for the medical technology industry from January 1998 until December 2001. From 1972 through 1999 Mr. Levande held a number of executive positions of increasing responsibility with Pfizer Inc., principally in its Medical Technology Group MTG, encompassing general management, operations, finance, marketing, and business development. Mr. Levande’s other experience includes serving as a director of Orthovita, Inc. from May 2000 to July 2007 and being the co-founder and director of VirnetX Inc., now VirnetX Holding Corp., from 2005 to 2007. He has been a director of theMaven, Inc. (formerly Integrated Surgical Systems) since 2008. He holds a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Columbia University.
Robert M. Levande,自2014年5月起担任董事,自2014年7月起担任董事长;2014年5月至2015年9月间担任副总裁。此外,他曾自我公司子公司NanoBlate Inc.和BioElectroMed Corp.于2014年11月成立起担任其唯一董事兼总裁,至2015年9月止。 他也是MDB Capital Group, LLC的高级常务董事,于2003年加入该公司。在加入MDB Capital Group, LLC之前,他于2001年12月至2003年5月间担任Gilford Securities的生命科学企业财务联席主管。此前,他成立了the Palantir Group, Inc., 1998年1月至2001年12月间,致力于为医疗技术行业提供业务开发、并购、筹资战略建议。1972年至1999年,他在Pfizer Inc.担任多个执行职位,级别渐升,主要在其医疗技术组(MTG),围绕一般管理、运营、财务、营销和业务开发。他的其他经验包括:Orthovita, Inc. (纳斯达克: VITA)的董事(2000.5-2007.7),VirnetX Inc.(现为VirnetX Holding Corp. (纽交所: MKT: VHC)的创始人/董事(2005-2007)。他自2008年起担任Integrated Surgical Systems (OTC: ISSM.PK)的董事。他获得了Columbia University的工商管理硕士学位,以及the University of Pennsylvania Wharton School of Finance & Commerce的经济学学士学位。
Robert M. Levande has been a member of our Board of Directors since May 2014 and Chairman of our Board of Directors since July 2015. Mr. Levande is one of our co-founders and a former officer of the Company. Mr. Levande is a senior managing director at MDB Capital Group, LLC, which he joined in 2003. Prior to joining MDB Capital Group, LLC, Mr. Levande was co-head of Life Sciences Corporate Finance at Gilford Securities Incorporated from December 2001 to May 2003. Previously, he founded the Palantir Group, Inc., which specializes in providing strategic advice in business development, mergers, acquisitions, and capital raising for the medical technology industry from January 1998 until December 2001. From 1972 through 1999 Mr. Levande held a number of executive positions of increasing responsibility with Pfizer Inc., principally in its Medical Technology Group MTG, encompassing general management, operations, finance, marketing, and business development. Mr. Levande’s other experience includes serving as a director of Orthovita, Inc. from May 2000 to July 2007 and being the co-founder and director of VirnetX Inc., now VirnetX Holding Corp., from 2005 to 2007. He has been a director of theMaven, Inc. (formerly Integrated Surgical Systems) since 2008. He holds a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Columbia University.
Mitchell E. Levinson

Mitchell E. Levinson,自2015年1月起担任董事;Zeltiq Aesthetics Inc.(成立于2005年)的创始首席执行官,2005年9月至2009年9月间担任其总裁兼首席执行官;2009年9月至2010年12月间担任首席科学官以帮助公司转型;2000年3月至2005年9月间担任Thermage, Inc.(后更名为Solta Medical,研究美容组织紧肤设备)的研发副总裁;1997年至2000年初担任BioSurgical Corporation (被Baxter收购,开发新型专用纤维蛋白密封敷抹技术)的工程副总裁;1994年至1997年间担任the Perinatal Division of Nellcor Puritan Bennett围产期部门的高级工程经理及产品开发主管;1991年至1994年间担任Baxter Diagnostics, Inc.显微扫描部门工程经理,并在Baxter Healthcare, Alcoa和Hewlett-Packard担任其他工程及管理职位。他是美国31项批准专利以及大量待批准专利的发明人。他获得了圣地亚哥University of California的机械工程学士学位,以及the University of Phoenix的计算机系统硕士学位。


Mitchell E. Levinson has been a member of our Board of Directors since January 2015. Mr. Levinson is currently President and Chief Executive Officer of Cerebrotech Medical Systems, a start-up medical device company he co-founded in 2010 focusing on noninvasive continuous monitoring for early detection of cerebral bleeding and edema. Prior to 2010 Mr. Levinson was the start-up CEO for Zeltiq Aesthetics Inc. when he became its first employee in 2005 and served as its president and its Chief Executive Officer from September 2005 until September 2009. He continued with Zeltiq as Chief Scientific Officer from September 2009 through December 2010 to help transition the company. From March 2000 to September 2005 he served as Vice President of Research and Development of Thermage, Inc. later renamed Solta Medical, a company engaged in cosmetic tissue tightening devices. He is the inventor of 41 issued and numerous pending U.S. patents. Mr. Levinson earned his BS in Mechanical Engineering from University of California at San Diego and holds an M.S in Computer Systems from the University of Phoenix.
Mitchell E. Levinson,自2015年1月起担任董事;Zeltiq Aesthetics Inc.(成立于2005年)的创始首席执行官,2005年9月至2009年9月间担任其总裁兼首席执行官;2009年9月至2010年12月间担任首席科学官以帮助公司转型;2000年3月至2005年9月间担任Thermage, Inc.(后更名为Solta Medical,研究美容组织紧肤设备)的研发副总裁;1997年至2000年初担任BioSurgical Corporation (被Baxter收购,开发新型专用纤维蛋白密封敷抹技术)的工程副总裁;1994年至1997年间担任the Perinatal Division of Nellcor Puritan Bennett围产期部门的高级工程经理及产品开发主管;1991年至1994年间担任Baxter Diagnostics, Inc.显微扫描部门工程经理,并在Baxter Healthcare, Alcoa和Hewlett-Packard担任其他工程及管理职位。他是美国31项批准专利以及大量待批准专利的发明人。他获得了圣地亚哥University of California的机械工程学士学位,以及the University of Phoenix的计算机系统硕士学位。
Mitchell E. Levinson has been a member of our Board of Directors since January 2015. Mr. Levinson is currently President and Chief Executive Officer of Cerebrotech Medical Systems, a start-up medical device company he co-founded in 2010 focusing on noninvasive continuous monitoring for early detection of cerebral bleeding and edema. Prior to 2010 Mr. Levinson was the start-up CEO for Zeltiq Aesthetics Inc. when he became its first employee in 2005 and served as its president and its Chief Executive Officer from September 2005 until September 2009. He continued with Zeltiq as Chief Scientific Officer from September 2009 through December 2010 to help transition the company. From March 2000 to September 2005 he served as Vice President of Research and Development of Thermage, Inc. later renamed Solta Medical, a company engaged in cosmetic tissue tightening devices. He is the inventor of 41 issued and numerous pending U.S. patents. Mr. Levinson earned his BS in Mechanical Engineering from University of California at San Diego and holds an M.S in Computer Systems from the University of Phoenix.
Thierry B. Thaure

Thierry B. Thaure,自2015年6月起担任董事;2012年11月联合成立Cephea Valve Technologies(开发经皮放置二尖瓣置换技术);自Cephea Valve Technologies, Inc成立起担任其首席执行官;此前于2011年6月至2012年6月间担任Mauna Kea Technologies, Inc.(全球医疗器械公司,关注显微内镜的创新)的首席执行官兼董事;2005年至2011年间担任EndoGastric Solutions Inc.(前称EsophyX Inc.)的首席执行官;此前担任Accuray Incorporated的销售及营销执行副总裁 (2001-2004), Intuitive Surgical Inc的销售及营销副总裁(1997-2000),以及Origin Medsystems和 Advanced Cardiovascular System的领导,二者均为the Guidant Corporation的分支机构。他在医疗器械领域的事业起步于Bentley and Edwards Laboratories的工程部门,这是Baxter International的一部分。1995年至1997年,他担任了Origin Medsystems, Inc.的国际业务主管。他获得了Duke University的化学和生物医学工程学士学位,以及the J.L. Kellogg Graduate School of Management at Northwestern University的工商管理硕士学位。


Thierry B. Thaure has been a member of our Board of Directors since June 2015. In November 2012 he co-founded Cephea Valve Technologies, a company that has developed a percutaneous placed Mitral Valve replacement technology. Mr. Thaure has been the Chief Executive Officer at Cephea Valve Technologies, Inc. since its creation. Prior to Cephea, Mr. Thaure was Chief Executive Officer and a board member of Mauna Kea Technologies, Inc., a global medical device company focused on leading innovation in endomicroscopy, from June 2011 to June 2012. Mr. Thaure previously served as the Chief Executive Officer of EndoGastric Solutions Inc. formerly EsophyX Inc. between 2005 and 2011. Prior to 2005 Mr. Thaure served as the Executive Vice President of Sales and Marketing of Accuray Incorporated (2001 to 2004), Vice President for Sales and Marketing of Intuitive Surgical, Inc. (1997-2000) and he also has served in leadership roles at Origin Medsystems and Advanced Cardiovascular System, both of which became divisions of the Guidant Corporation. Mr. Thaure started his medical device career at Bentley and Edwards Laboratories in the engineering departments, which is a part of Baxter International. From 1995 to 1997 he served as Director for International Business of Origin Medsystems, Inc. Mr. Thaure holds B.S. in Chemistry and Biomedical Engineering from Duke University and his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
Thierry B. Thaure,自2015年6月起担任董事;2012年11月联合成立Cephea Valve Technologies(开发经皮放置二尖瓣置换技术);自Cephea Valve Technologies, Inc成立起担任其首席执行官;此前于2011年6月至2012年6月间担任Mauna Kea Technologies, Inc.(全球医疗器械公司,关注显微内镜的创新)的首席执行官兼董事;2005年至2011年间担任EndoGastric Solutions Inc.(前称EsophyX Inc.)的首席执行官;此前担任Accuray Incorporated的销售及营销执行副总裁 (2001-2004), Intuitive Surgical Inc的销售及营销副总裁(1997-2000),以及Origin Medsystems和 Advanced Cardiovascular System的领导,二者均为the Guidant Corporation的分支机构。他在医疗器械领域的事业起步于Bentley and Edwards Laboratories的工程部门,这是Baxter International的一部分。1995年至1997年,他担任了Origin Medsystems, Inc.的国际业务主管。他获得了Duke University的化学和生物医学工程学士学位,以及the J.L. Kellogg Graduate School of Management at Northwestern University的工商管理硕士学位。
Thierry B. Thaure has been a member of our Board of Directors since June 2015. In November 2012 he co-founded Cephea Valve Technologies, a company that has developed a percutaneous placed Mitral Valve replacement technology. Mr. Thaure has been the Chief Executive Officer at Cephea Valve Technologies, Inc. since its creation. Prior to Cephea, Mr. Thaure was Chief Executive Officer and a board member of Mauna Kea Technologies, Inc., a global medical device company focused on leading innovation in endomicroscopy, from June 2011 to June 2012. Mr. Thaure previously served as the Chief Executive Officer of EndoGastric Solutions Inc. formerly EsophyX Inc. between 2005 and 2011. Prior to 2005 Mr. Thaure served as the Executive Vice President of Sales and Marketing of Accuray Incorporated (2001 to 2004), Vice President for Sales and Marketing of Intuitive Surgical, Inc. (1997-2000) and he also has served in leadership roles at Origin Medsystems and Advanced Cardiovascular System, both of which became divisions of the Guidant Corporation. Mr. Thaure started his medical device career at Bentley and Edwards Laboratories in the engineering departments, which is a part of Baxter International. From 1995 to 1997 he served as Director for International Business of Origin Medsystems, Inc. Mr. Thaure holds B.S. in Chemistry and Biomedical Engineering from Duke University and his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
Maky Zanganeh

Maky Zanganeh于2017年2月被任命为我们的董事会成员。Zanganeh博士目前是Zanganeh and Associates的总裁,此前曾于2012年8月至2015年9月担任Pharmacyclics Inc.的首席运营官,2011年12月至2012年7月担任参谋长兼首席商务官,2008年8月至2011年11月担任业务发展Vice President。加入Pharmacyclics Inc.之前,Zanganeh从2007年到2008年担任法国政府倡议生物集群项目(French Government Initiative Bio-Cluster Project)总裁,在地区范围内建立联盟和发展小型生命科学业务。2003年9月至2008年8月,Zanganeh博士担任RobertW.Duggan&Associates的业务发展Vice President。Zanganeh博士还曾担任世界医疗机器人技术发起者Computer Motion Inc.的全球培训和教育Vice President(2002-2003年)和欧洲、中东和非洲地区总裁(1998-2002年)。Zanganeh博士在法国斯特拉斯堡Louis Pasteur University获得DDS学位,在法国Schiller International University获得工商管理硕士学位。


Maky Zanganeh was appointed to our Board of Directors in February 2017. Dr. Zanganeh is currently President of Zanganeh and Associates and previously served as the Chief Operating Officer of Pharmacyclics Inc. from August 2012 to September 2015 Chief of Staff and Chief Business Officer from December 2011 to July 2012 and Vice President, Business Development August 2008 to November 2011. Prior joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General 2007-2008 for the French government initiative bio-cluster project in France, establishing alliances and developing small life science business regionally. From September 2003 to August 2008 Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan & Associates. Dr. Zanganeh also served as worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France.
Maky Zanganeh于2017年2月被任命为我们的董事会成员。Zanganeh博士目前是Zanganeh and Associates的总裁,此前曾于2012年8月至2015年9月担任Pharmacyclics Inc.的首席运营官,2011年12月至2012年7月担任参谋长兼首席商务官,2008年8月至2011年11月担任业务发展Vice President。加入Pharmacyclics Inc.之前,Zanganeh从2007年到2008年担任法国政府倡议生物集群项目(French Government Initiative Bio-Cluster Project)总裁,在地区范围内建立联盟和发展小型生命科学业务。2003年9月至2008年8月,Zanganeh博士担任RobertW.Duggan&Associates的业务发展Vice President。Zanganeh博士还曾担任世界医疗机器人技术发起者Computer Motion Inc.的全球培训和教育Vice President(2002-2003年)和欧洲、中东和非洲地区总裁(1998-2002年)。Zanganeh博士在法国斯特拉斯堡Louis Pasteur University获得DDS学位,在法国Schiller International University获得工商管理硕士学位。
Maky Zanganeh was appointed to our Board of Directors in February 2017. Dr. Zanganeh is currently President of Zanganeh and Associates and previously served as the Chief Operating Officer of Pharmacyclics Inc. from August 2012 to September 2015 Chief of Staff and Chief Business Officer from December 2011 to July 2012 and Vice President, Business Development August 2008 to November 2011. Prior joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General 2007-2008 for the French government initiative bio-cluster project in France, establishing alliances and developing small life science business regionally. From September 2003 to August 2008 Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan & Associates. Dr. Zanganeh also served as worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France.

高管简历

中英对照 |  中文 |  英文
Darrin R. Uecker

Darrin R. Uecker,自2015年9月起担任首席执行官、总裁兼董事。他有着超过20年的医疗器械领域经验。他于2014年1月至2015年9月间担任加州门罗帕克市Progyny, Inc.(开发EevaTM,这是世界上第一个在体外受精时进行受精卵筛选的自动延时系统)的总裁兼首席运营官;2009年6月至2014年1月间担任加州雷德伍德城Gynesonics, Inc.(利用超声引导射频消融技术开发针对症状性子宫肌瘤疗法的新型医疗器械)的首席执行官、总裁兼董事;2008年6月至2009年6月间担任CyperHeart, Inc.(开发外辐射平台,用于治疗心律失常)的高级副总裁等多个职位;2007年5月至2008年6月间担任Conceptus, Inc.的高级副总裁,2004年1月至2007年1月间担任RITA Medical Systems, Inc.(医疗器械公司,关注肿瘤治疗的烧灼疗法)的首席技术官。他被任命为董事是由于他在圣塔芭芭拉the University of California电子和计算机工程的教育背景。


Darrin R. Uecker has been our Chief Executive Officer and President and a director since September 2015. Mr. Uecker has over 20 years of experience in the medical device field. From January 2014 to September 2015 Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. From June 2009 to January 2014 Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Prior to that, Mr. Uecker served in a variety of executive level roles, including as a Senior Vice President at CyperHeart, Inc. June 2008 to June 2009 a company that developed an external beam radiation platform for the treatment of heart arrhythmias, a Senior Vice President at Conceptus, Inc. (May 2007 to June 2008), and as Chief Technology Officer at RITA Medical Systems, Inc. (January 2004 to January 2007), a medical device oncology company focused on ablative therapies. Mr. Uecker holds a M.S. degree in Electrical and Computer Engineering from the University of California at Santa Barbara.
Darrin R. Uecker,自2015年9月起担任首席执行官、总裁兼董事。他有着超过20年的医疗器械领域经验。他于2014年1月至2015年9月间担任加州门罗帕克市Progyny, Inc.(开发EevaTM,这是世界上第一个在体外受精时进行受精卵筛选的自动延时系统)的总裁兼首席运营官;2009年6月至2014年1月间担任加州雷德伍德城Gynesonics, Inc.(利用超声引导射频消融技术开发针对症状性子宫肌瘤疗法的新型医疗器械)的首席执行官、总裁兼董事;2008年6月至2009年6月间担任CyperHeart, Inc.(开发外辐射平台,用于治疗心律失常)的高级副总裁等多个职位;2007年5月至2008年6月间担任Conceptus, Inc.的高级副总裁,2004年1月至2007年1月间担任RITA Medical Systems, Inc.(医疗器械公司,关注肿瘤治疗的烧灼疗法)的首席技术官。他被任命为董事是由于他在圣塔芭芭拉the University of California电子和计算机工程的教育背景。
Darrin R. Uecker has been our Chief Executive Officer and President and a director since September 2015. Mr. Uecker has over 20 years of experience in the medical device field. From January 2014 to September 2015 Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. From June 2009 to January 2014 Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Prior to that, Mr. Uecker served in a variety of executive level roles, including as a Senior Vice President at CyperHeart, Inc. June 2008 to June 2009 a company that developed an external beam radiation platform for the treatment of heart arrhythmias, a Senior Vice President at Conceptus, Inc. (May 2007 to June 2008), and as Chief Technology Officer at RITA Medical Systems, Inc. (January 2004 to January 2007), a medical device oncology company focused on ablative therapies. Mr. Uecker holds a M.S. degree in Electrical and Computer Engineering from the University of California at Santa Barbara.
Brian B. Dow

Brian B. Dow,自2015年11月起担任首席财务官、高级副总裁、财务主管兼秘书;此前于2015年5月至2015年11月间担任Progyny, Inc.的首席财务官;2010年5月至2015年4月间担任Pacific Biosciences of California(纳斯达克: PACB,下一代基因测序仪器大型制造商)的副总裁兼主要会计官;2006年1月至2010年5月间担任Northstar Neuroscience, Inc. (纳斯达克: NSTR,发展阶段医疗器械公司)的多个财务官职位,最近担任首席财务官;2006年之前,他有14年是在上市公司和公共会计公司担任财务管理职位,级别渐升,曾担任 Ernst and Young的经理。他是华盛顿的注册会计师,获得了the Georgia Institute of Technology的管理学学士学位。


Brian B. Dow has been our Chief Financial Officer, Senior Vice President, Treasurer and Secretary since November 2015. Prior to joining us, Mr. Dow served as the Chief Financial Officer of Progyny, Inc. from May 2015 to November 2015. From May 2010 to April 2015 Mr. Dow was the Vice President and Principal Accounting Officer of Pacific Biosciences of California NASDAQ: PACB, a leading provider of next generation genetic sequencing instruments. Mr. Dow held a series of financial officer positions with Northstar Neuroscience, Inc. (NASDAQ: NSTR), a development stage medical device company, from January 2006 to May 2010 most recently serving as the Chief Financial Officer. Prior to 2006 Mr. Dow had 14 years of progressively-increasing responsibilities in financial management of publicly-traded companies and in public accounting as a manager with Ernst and Young. Mr. Dow is recognized as a licensed Certified Public Accountant by the State of Washington Board of Accountancy and holds a Bachelor of Science in Management from the Georgia Institute of Technology.
Brian B. Dow,自2015年11月起担任首席财务官、高级副总裁、财务主管兼秘书;此前于2015年5月至2015年11月间担任Progyny, Inc.的首席财务官;2010年5月至2015年4月间担任Pacific Biosciences of California(纳斯达克: PACB,下一代基因测序仪器大型制造商)的副总裁兼主要会计官;2006年1月至2010年5月间担任Northstar Neuroscience, Inc. (纳斯达克: NSTR,发展阶段医疗器械公司)的多个财务官职位,最近担任首席财务官;2006年之前,他有14年是在上市公司和公共会计公司担任财务管理职位,级别渐升,曾担任 Ernst and Young的经理。他是华盛顿的注册会计师,获得了the Georgia Institute of Technology的管理学学士学位。
Brian B. Dow has been our Chief Financial Officer, Senior Vice President, Treasurer and Secretary since November 2015. Prior to joining us, Mr. Dow served as the Chief Financial Officer of Progyny, Inc. from May 2015 to November 2015. From May 2010 to April 2015 Mr. Dow was the Vice President and Principal Accounting Officer of Pacific Biosciences of California NASDAQ: PACB, a leading provider of next generation genetic sequencing instruments. Mr. Dow held a series of financial officer positions with Northstar Neuroscience, Inc. (NASDAQ: NSTR), a development stage medical device company, from January 2006 to May 2010 most recently serving as the Chief Financial Officer. Prior to 2006 Mr. Dow had 14 years of progressively-increasing responsibilities in financial management of publicly-traded companies and in public accounting as a manager with Ernst and Young. Mr. Dow is recognized as a licensed Certified Public Accountant by the State of Washington Board of Accountancy and holds a Bachelor of Science in Management from the Georgia Institute of Technology.